MacroGenics (NASDAQ: MGNX) and Biopharma Peers: An ROIC vs. WACC Analysis

• MacroGenics, Inc. (NASDAQ: MGNX) currently reports a Weighted Average Cost of Capital (WACC) of 9.08% and a Return on Invested Capital (ROIC) of -49.59%, indicating it is not yet generating profit from its investments, a common scenario for clinical-stage biopharmaceutical companies.
• The biopharmaceutical sector faces significant capital challenges, with peers like Xencor, Karyopharm Therapeutics, and Atara Biotherapeutics also exhibiting negative ROICs due to substantial research and development investments.
• Among its peers, CytomX Therapeutics demonstrates relatively better capital management, with an ROIC to WACC ratio of -1.40, despite its negative ROIC of -19.70%.

MacroGenics, Inc. (NASDAQ: MGNX) is a biopharmaceutical company that develops antibody-based treatments for cancer. It operates in a competitive field alongside peers like Xencor, Inc. (NASDAQ: XNCR), Karyopharm Therapeutics Inc. (NASDAQ: KPTI), CytomX Therapeutics, Inc. (NASDAQ: CTMX), and Atara Biotherapeutics, Inc. (NASDAQ: ATRA). These companies often require large investments for research and development.

A key way to measure a company's performance is by comparing its Return on Invested Capital (ROIC) to its Weighted Average Cost of Capital (WACC). WACC is the average cost a company pays to raise funds. ROIC measures the profit generated from those funds. A company creates value when its ROIC is higher than its WACC.

MGNX currently has a WACC of 9.08%. However, its ROIC is -49.59%. This means the company is not yet generating a profit on its investments. This situation is common for biopharmaceutical firms that are still in the clinical stage, investing heavily in research before their products are sold.

Looking at its peers, Xencor has an ROIC of -30.58% and a WACC of 9.91%. Karyopharm Therapeutics faces a high WACC of 16.13% with an ROIC of -177.79%. Atara Biotherapeutics has a lower WACC of 5.75% but an ROIC of -41.06%. These figures highlight the capital challenges within the sector.

Among this group, CytomX Therapeutics stands out. While its ROIC of -19.70% is negative, its ROIC to WACC ratio of -1.40 is the highest. This suggests CTMX is managing its capital more efficiently than its peers, even though it is not yet profitable on its investments.